About
Culture & Team
Our Story
We put YOU at the centre
of all our plans.
For Every Tomorrow
We will bring the safest, gentlest and most exciting new treatment method for GBM: Sonodynamic Therapy, to Europe and the wider world.
Richard and Jane lost their father to GBM during 2021, and didn’t manage to spend much time with him in the two months between diagnosis and him passing away.
They worked with cancer neuroscientists, neurosurgeons and biomedical engineers to create CureGBM to help preserve the memory of their cherished Dad, leaving a
We are grateful to our funders and investors, as their contributions will allow patients to be enrolled in our trials for FREE, enabling them and their families to concentrate their energy on fighting GBM.
Our Story
committing to excellence
Dedicated to pioneering a breakthrough in brain tumour treatment
Our Vision
To make 'terminal' treatable. For every tomorrow.
Our Mission
To build the clinical infrastructure that brings breakthrough brain tumour treatments to patients without delay.
ABOUT
Team
Richard Wakefield
Founder CureGBM
Mission
Richard’s commitment and reason for founding CureGBM is deeply personal. After losing his father to glioblastoma in 2021, Richard made it his mission to push forward meaningful change in the brain cancer space. Despite a busy family life as husband and father of two boys, he remains fully dedicated to making CureGBM a success. His drive is fuelled by love, loss, and a determination to ensure that no family faces GBM alone.
Richard brings a unique blend of discipline, resilience, and entrepreneurial drive to CureGBM. Having served in the British Army, he developed strong leadership and problem-solving skills that continue to shape his approach to building impactful initiatives.
Over the years, he has lived and worked across UK, Germany, Switzerland and Austria, now based in Vienna, successfully growing companies from the ground up into independent enterprises.
Richard leads with heart and purpose – turning personal tragedy into collective hope.
Jane Oberholzer
Patient Advocate CureGBM
Mission
Jane brings a deeply personal and compassionate perspective to CureGBM as its dedicated Patient Advocate. Having lived and worked in both London and Zurich, she balances a demanding career in asset management with a rich family life and active involvement in community philanthropy.
Her commitment to CureGBM is rooted in her own experience — when her father was diagnosed with glioblastoma (GBM), she faced the journey with minimal support. Today, she channels that experience into being a steady, empathetic presence for patients and families navigating the same path.
Jane ensures that no one feels alone, offering a listening ear, heartfelt guidance, and unwavering advocacy. Her role is not just professional — it’s profoundly personal, and her impact resonates in every life she touches.
MEET THE TEAM
Advisory Panel
Prof. Philippe Schucht
Deputy Head of Neurosurgery,
Inselspital University Hospital Bern
Clinical Credibility and Global Neurosurgical Leadership
Prof. Philippe Schucht is Deputy Head of Neurosurgery at Inselspital, University Hospital Bern, and Professor of Neurosurgery at the University of Bern. He specialises in neuro-oncological surgery, vascular neurosurgery, and advanced intraoperative imaging, leading the Centre for Neuro-Oncology at Inselspital where he shapes both clinical practice and research. Recognised for his clinical precision and academic depth, he is a pioneer in focused ultrasound delivery for glioblastoma, bridging cutting-edge technology with day-to-day neurosurgical decision-making to evaluate emerging treatments like SDT with clinical realism.
Why it matters for SDT
Philippe ensures SDT remains clinically grounded, targeting real patient needs. His global academic and professional networks accelerate clinical trial access, regulatory support, and medical community buy-in.
Prof. Francesco Prada
Neurosurgeon and Scientist,
Istituto Neurologico Carlo Besta Milan
Translational Neuroscience and Focused Ultrasound Expertise
Prof. Francesco Prada is a neurosurgeon and scientist at the Istituto Neurologico Carlo Besta in Milan, Senior Advisor to the Focused Ultrasound Foundation, and Associate Professor at the University of Virginia. He directs the Acoustic Neuroimaging and Therapy Lab, advancing ultrasound-mediated imaging and therapeutic technologies for the central nervous system, and leads the first European clinical trial of sonodynamic therapy for glioblastoma. His combined roles across clinical neurosurgery, translational research, and global focused ultrasound leadership place him at the exact intersection where scientific credibility, clinical translation, and the future of ultrasound-enabled neuro-oncology meet.
Why it matters for SDT
Francesco sits at the exact intersection where scientific credibility, clinical translation, and investor confidence meet. In a field as young and technically demanding as sonodynamic therapy, that combination is rare and incredibly valuable.
Dr. James Joseph
Senior Lecturer in Biomedical Engineering,
University of Dundee
Pioneer in Multimodal Ultrasound–Optical Imaging and Translational Biomedical Engineering
Dr. James Joseph is a Senior Lecturer in Biomedical Engineering at the University of Dundee, with expertise spanning multimodal imaging, photonics, ultrasonics, and hybrid imaging system development across the University of Cambridge, Nanyang Technological University, and Dundee. He has built world-first integrated platforms combining photoacoustics, ultrasound, and fluorescence imaging, advancing optical, acoustic, and hybrid modalities for both preclinical and clinical use over more than a decade. He operates at the technical frontier of next-generation biomedical imaging, and has applied this expertise to developing an in vivo platform for optimising SDT sonication parameters.
Why it matters for SDT
James sits at the cutting edge where imaging physics, device engineering, and translational feasibility converge. Sonodynamic therapy is fundamentally an ultrasound imaging-dependent therapeutic modality, requiring precise energy delivery, real-time monitoring, and a deep understanding of acoustic-optical interactions.
Alan Noble
Entrepreneur, Advisor, and Professor of Entrepreneurship
Webster University Vienna
Financial Stewardship and Venture-Building Expertise
Alan Noble is a former board-level executive in Citibank’s Corporate and Investment Banking Group across multiple European markets, with deep expertise in capital strategy, risk management, and how institutional investors evaluate emerging technologies. After successfully founding, growing, and exiting his own company, he now advises high-growth ventures on business strategy, finance, governance, and operational excellence. He is also a Professor of Entrepreneurship at Webster University in Vienna.
Why it matters for SDT
Alan ensures the company is built on a foundation of financial rigour, strategic clarity, and investor-grade governance. His experience on both sides of the table — corporate finance and entrepreneurial execution — strengthens our fundraising strategy, sharpens our commercial model, and positions SDT as a credible, scalable investment opportunity.